{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:09:45Z","timestamp":1791180585890,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T00:00:00Z","timestamp":1294704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00198-010-1525-6","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T15:33:17Z","timestamp":1294673597000},"page":"1171-1176","source":"Crossref","is-referenced-by-count":95,"title":["Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women\u2014the six-month effect of risedronate and teriparatide"],"prefix":"10.1007","volume":"23","author":[{"given":"S. A.","family":"Polyzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bratengeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Woloszczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Papatheodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,11]]},"reference":[{"key":"1525_CR1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","volume":"87","author":"MJ Moester","year":"2010","unstructured":"Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99\u2013107","journal-title":"Calcif Tissue Int"},{"key":"1525_CR2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/156652410791065372","volume":"10","author":"R Trivedi","year":"2010","unstructured":"Trivedi R, Mithal A, Chattopadhyay N (2010) Anabolics in osteoporosis: the emerging therapeutic tool. Curr Mol Med 10:14\u201328","journal-title":"Curr Mol Med"},{"key":"1525_CR3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van HW (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537\u2013543","journal-title":"Hum Mol Genet"},{"key":"1525_CR4","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","volume":"19","author":"KE Poole","year":"2005","unstructured":"Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842\u20131844","journal-title":"FASEB J"},{"key":"1525_CR5","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883\u201319887","journal-title":"J Biol Chem"},{"key":"1525_CR6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nature756","volume":"417","author":"B Mao","year":"2002","unstructured":"Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C (2002) Kremen proteins are Dickkopf receptors that regulate Wnt\/beta-catenin signalling. Nature 417:664\u2013667","journal-title":"Nature"},{"key":"1525_CR7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/14728210902766813","volume":"14","author":"EM Lewiecki","year":"2009","unstructured":"Lewiecki EM (2009) Emerging drugs for postmenopausal osteoporosis. Expert Opin Emerg Drugs 14:129\u2013144","journal-title":"Expert Opin Emerg Drugs"},{"key":"1525_CR8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bone.2010.05.032","volume":"47","author":"X Tian","year":"2010","unstructured":"Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47:529\u2013533","journal-title":"Bone"},{"key":"1525_CR9","author":"D Padhi","year":"2010","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2010) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. doi: 10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"key":"1525_CR10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1742-1241.2008.01768.x","volume":"62","author":"AD Anastasilakis","year":"2008","unstructured":"Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A (2008) Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract 62:919\u2013924","journal-title":"Int J Clin Pract"},{"key":"1525_CR11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2008-1046787","volume":"40","author":"AD Anastasilakis","year":"2008","unstructured":"Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A (2008) Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res 40:281\u2013285","journal-title":"Horm Metab Res"},{"key":"1525_CR12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2265.2009.03728.x","volume":"72","author":"AD Anastasilakis","year":"2010","unstructured":"Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E (2010) The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol Oxf 72:752\u2013757","journal-title":"Clin Endocrinol Oxf"},{"key":"1525_CR13","author":"UI Modder","year":"2010","unstructured":"Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Lawrence RB, Joseph ML III, Khosla S (2010) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. doi: 10.1002\/jbmr.217","journal-title":"J Bone Miner Res"},{"key":"1525_CR14","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1007\/s00198-005-1871-y","volume":"16","author":"LJ Melton III","year":"2005","unstructured":"Melton LJ III, Looker AC, Shepherd JA, O\u2019Connor MK, Achenbach SJ, Riggs BL, Khosla S (2005) Osteoporosis assessment by whole body region vs. site-specific DXA. Osteoporos Int 16:1558\u20131564","journal-title":"Osteoporos Int"},{"key":"1525_CR15","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2010-0720","volume":"95","author":"MT Drake","year":"2010","unstructured":"Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056\u20135062","journal-title":"J Clin Endocrinol Metab"},{"key":"1525_CR16","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","volume":"95","author":"FS Mirza","year":"2010","unstructured":"Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991\u20131997","journal-title":"J Clin Endocrinol Metab"},{"key":"1525_CR17","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1210\/jc.2010-0067","volume":"95","author":"A Gaudio","year":"2010","unstructured":"Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248\u20132253","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-010-1525-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-010-1525-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-010-1525-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T18:54:51Z","timestamp":1559933691000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-010-1525-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,11]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s00198-010-1525-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,11]]}}}